Turner C H, Sato M, Bryant H U
Department of Ortopaedic Surgery, Indiana University Medical Center, Indianapolis 46202.
Endocrinology. 1994 Nov;135(5):2001-5. doi: 10.1210/endo.135.5.7956922.
We investigated the effects of raloxifene, a nonsteroidal benzothiophene, on bone strength in ovariectomized rats and compared them with estrogen treatment. Sixty ovariectomized Sprague-Dawley rats were divided into three groups for treatment with orally dosed raloxifene (3 mg/kg), ethynyl estradiol (EE, 0.1 mg/kg), or vehicle. A fourth group of 20 rats that underwent sham ovariectomies and received vehicle was used for comparison. Treatments began 3 days after ovariectomy and continued for 6 months. Raloxifene treatment resulted in greater bone strength in the lumbar vertebrae (P < 0.05) and femoral neck (P < 0.01) and greater bone mineral density at the proximal tibia (P < 0.001) and lumbar vertebrae (P < 0.001) when compared with vehicle-treated ovariectomized animals. The positive effects on bone biomechanical properties from raloxifene treatment were not different than those associated with EE treatment. Raloxifene did not cause a significant increase in uterine weight, whereas EE treatment resulted in uterine weight increased 4-fold over vehicle-treated ovariectomized controls. Therefore, in rats, raloxifene has beneficial effects on bone biomechanics that are equivalent to those of EE treatment without substantial effects on the uterus.
我们研究了非甾体类苯并噻吩雷洛昔芬对去卵巢大鼠骨强度的影响，并将其与雌激素治疗效果进行比较。将60只去卵巢的斯普拉格-道利大鼠分为三组，分别口服给予雷洛昔芬（3毫克/千克）、乙炔雌二醇（EE，0.1毫克/千克）或赋形剂。另外选取20只接受假去卵巢手术并给予赋形剂的大鼠作为第四组用于对照。去卵巢3天后开始给药，持续6个月。与接受赋形剂治疗的去卵巢动物相比，雷洛昔芬治疗使腰椎（P<0.05）和股骨颈（P<0.01）的骨强度更高，胫骨近端（P<0.001）和腰椎（P<0.001）的骨矿物质密度更高。雷洛昔芬治疗对骨生物力学特性的积极影响与EE治疗的效果没有差异。雷洛昔芬不会使子宫重量显著增加，而EE治疗导致子宫重量比接受赋形剂治疗的去卵巢对照增加了4倍。因此，在大鼠中，雷洛昔芬对骨生物力学具有有益作用，其效果与EE治疗相当，且对子宫无实质性影响。
